Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis by Cardaci, Simone et al.
n 
 
 
 
 
 
Cardaci, S. et al. (2015) Pyruvate carboxylation enables growth of SDH-deficient 
cells by supporting aspartate biosynthesis. Nature Cell Biology, 17, pp. 1317-1326. 
 
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
 
 
 
 
 
http://eprints.gla.ac.uk/109853/    
 
 
 
 
 
 
Deposited on: 25 January 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
Pyruvate carboxylation enables growth of SDH-deficient cells by 
supporting aspartate biosynthesis 
Simone Cardaci1, Liang Zheng1, Gillian MacKay1, Niels J.F. van den Broek1, Elaine D. 
MacKenzie1, Colin Nixon1, David Stevenson1, Sergey Tumanov1,2, Vinay Bulusu1,2, Jurre J. 
Kamphorst1,2 , Alexei Vazquez1, Stewart Fleming3, Francesca Schiavi4, Gabriela Kalna1, Karen 
Blyth1, Douglas Strathdee1 and Eyal Gottlieb1* 
 
1Cancer Research UK, Beatson Institute, Switchback Rd, Glasgow, G61 1BD, UK 
2Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1BD, UK 
3Department of Pathology, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK 
4Veneto Institute of Oncology IRCCS, Familial cancer clinic and oncoendocrinology, Via 
Gattamelata 64, 35128 Padova, Italy 
 
*Correspondence: e.gottlieb@beatson.gla.ac.uk 
 
 
ABSTRACT 
 
Succinate dehydrogenase (SDH) is a hetero-tetrameric nuclear-encoded complex responsible 
for the oxidation of succinate to fumarate in the tricarboxylic acid (TCA) cycle. Loss-of-
function mutations in any of the SDH genes are associated with cancer formation. However, 
the impact of SDH loss on cell metabolism and the mechanisms enabling growth of SDH-
defective cells are largely unknown. Here, we generated Sdhb-ablated kidney mouse cells and 
employed comparative metabolomics and stable isotope-labelling approaches to identify 
nutritional requirements and metabolic adaptations to SDH loss. We found that lack of SDH 
activity commits cells to consume extracellular pyruvate, which sustains Warburg-
like bioenergetic features. We further demonstrated that pyruvate carboxylation diverts 
glucose-derived carbons into aspartate biosynthesis, thus sustaining cell growth. By 
identifying pyruvate carboxylase as an essential gene for the proliferation and tumorigenic 
capacity of SDH-deficient cells, this study revealed a metabolic vulnerability for potential 
future treatment of SDH-associated malignancies. 
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INTRODUCTION 
TCA cycle is a pivotal source for mitochondrial NADH and the core metabolic route for production 
of many biosynthetic precursors. Over the last fifteen years, oncogenic mutations in three TCA 
cycle-related enzymes, SDH, fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) have 
been identified1. While these discoveries may implicate altered metabolism as an underlying 
hallmark of neoplastic transformation, they left the question how these cancer cells fulfil 
bioenergetic and anabolic demands largely unresolved.  
SDH is a hetero-tetrameric nuclear-encoded protein complex responsible for oxidation of 
succinate to fumarate in the TCA cycle and for feeding electrons into the mitochondrial respiratory 
chain for ATP production (complex II). Inactivating mutations in the human genes for any of the 
SDH subunits, or the SDH complex assembly factor (SDHAF2), are associated with susceptibility 
to develop neuroendrocrine neoplasms, gastrointestinal stromal tumours as well as renal cell 
carcinoma (RCC)2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13. Loss of SDH causes succinate accumulation in cells, 
which activates hypoxia-inducible factors at normal oxygen tension and inhibits α-ketoglutarate-
dependent histone and DNA demethylases, thereby establishing, respectively, a pseudohypoxic and 
hypermethylator phenotype in tumours14, 15, 16. 
Although SDH is the first discovered TCA cycle enzyme with tumour suppressor properties, 
the metabolic consequences of SDH disabling and the molecular mechanisms enabling survival and 
growth of SDH-defective cells remain largely unexplored. Knowledge of metabolic profile of SDH-
mutated tumours is limited and largely inferred from few steady-state metabolic changes observed 
in situ in human studies. However, whereas pan-metabolomic analyses are useful to identify 
biochemical signatures for tumour stratification, they do not allow for the understanding of 
biochemical fluxes necessary to disclose targetable cancer metabolic vulnerabilities. Considering 
this limitation, the RNA interference-mediated silencing of SDH subunits in cancer cell allowed a 
partial understanding of cellular effects of mitochondrial complex II deficiency14, 17, 18. However, as 
SDH levels are never completely depleted by RNAi, the residual SDH activity might still play a 
role in succinate oxidation in mitochondria, thereby masking the effective rewiring of metabolic 
networks in tumours devoid of functional SDH. To overcome this limitation, we generated Sdhb-
ablated immortalized kidney mouse cells and by unsupervised metabolomic screenings and isotope-
labelling approaches we identified metabolic pathways essential to support their proliferation. We 
found that SDHB loss is sufficient to ensure a complete block of the TCA cycle and to 
drive Warburg-like bioenergetic features of aerobic glycolysis in proliferating cells. We 
demonstrated that ablation of SDH activity commits cells to consume extracellular pyruvate needed 
to sustain maximal glycolytic flux and support the diversion of glucose-derived carbons into 
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aspartate biosynthesis via pyruvate carboxylase (PCX for mouse and PC for human). By identifying 
Pcx as an essential gene for SDH-deficient but dispensable for normal cells, this study unveils a 
metabolic vulnerability for potential treatment of SDH-associated neoplasms. 
 
RESULTS 
Sdhb deletion induces complete truncation of the TCA cycle and commits cells to fulfill 
energetic needs through glycolysis  
To predict and validate metabolic alterations induced by FH loss, we previously used genetically 
modified kidney mouse cells in which Fh1 has been deleted19, 20, 21. Similarly, to disclose metabolic 
rewiring induced by SDH loss, we first produced genetically modified mice containing LoxP sites 
flanking exon 3 of the endogenous Sdhb gene (Supplementary Fig. 1a) and then immortalized 
primary kidney epithelial cells isolated from these mice (Sdhbfl/fl). To generate Sdhb knockout cells 
(SdhbΔ/Δ), Sdhbfl/fl cells were infected with recombinant adenovirus expressing Cre recombinase. 
Two clones (SdhbΔ/Δ - CL 5 and SdhbΔ/Δ - CL 7) were selected from the infected pool and 
genetically confirmed to contain homozygous Sdhb-deleted alleles (Supplementary Fig. 1b, c). 
Suppression of exon 3 leads to a premature stop codon and, as a result, SdhbΔ/Δ cells presented with 
a complete loss of SDHB protein production and complete impairment of the overall SDH complex 
activity (Supplementary Fig. 1d, e). Carbon supply to the TCA cycle is achieved mainly through the 
catabolism of glucose and glutamine. Therefore, to reveal the effects of SDHB loss on TCA cycle 
function, cells were cultured in medium containing uniformly labelled U-13C-glucose or U-13C-
glutamine, and the 13C-labelling of succinate and fumarate was analysed by liquid chromatography-
mass spectrometry (LC-MS). SDHB loss gave rise to a build-up of intracellular succinate, which 
reached levels approximately 200-fold higher than that of Sdhbfl/fl cells, and a concomitant decrease 
of fumarate (Fig. 1a-d). When U-13C-glucose was used, less than 15% of cellular succinate was 
labelled (Fig. 1a). However, over 80% of the succinate was fully labelled (13C4) when cells were 
cultured with U-13C-glutamine (Fig. 1b), indicating that glutamine is a major source of carbons for 
the TCA cycle in both Sdhbfl/fl and SdhbΔ/Δ cells. Importantly, the fumarate pool of the Sdhbfl/fl cells 
fed with either 13C6-labelled glucose or 13C5-labelled glutamine contained considerable fractions of 
isotopologues with 2 and 4 13C atoms respectively, due to the processing of succinate in and beyond 
the SDH step (Fig. 1c, d). The absence of these isotopologues in SdhbΔ/Δ cells demonstrates that loss 
of SDHB is sufficient for blocking the TCA cycle (Fig. 1c, d). FADH2, generated during SDH 
catalysis and NADH, produced mainly in the mitochondria by other dehydrogenases, feed the 
respiratory chain for oxygen consumption and ATP production. Therefore, the effects of complex II 
deficiency and TCA cycle truncation on the oxygen consumption rate (OCR) of SDH-null cells 
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were investigated. Sdhb-deficient clones display lower basal mitochondrial respiration with respect 
to SDH-proficient cells (Fig. 1e). This feature was strongly associated with a reduced entry of 
glucose carbons into the TCA cycle via pyruvate dehydrogenase as indicated by the diminished 
pool of citrate containing two 13C atoms in SDHB-null cells fed with U-13C-glucose with respect to 
normal counterparts (Fig. 1f). In line with this finding, lower labelling of lipogenic acetyl-CoA 
(AcCoA) from glucose was observed in SDH-null cells compared to their normal counterparts 
(Supplementary Fig. 1f). On the contrary, glutamine represents the main source of labelled 
lipogenic AcCoA when SDHB is lost (Supplementary Fig. 1f). In-depth analysis of the respiratory 
profile indicated that whereas under basal conditions Sdhbfl/fl cells consume molecular oxygen at a 
sub-maximal capacity, both the maximal OCR and the reserve capacity are reduced upon SDH loss, 
indicating that SdhbΔ/Δ cells respire at a rate close to their bioenergetic limit (Fig. 1e and 
Supplementary Fig. 2a). Importantly, the near complete loss of oxygen consumption is not due to a 
reduction in the number of mitochondria. Indeed, as observed in SDHB-associated renal cell 
tumours22, SDH-null cells display an increase in mitochondrial mass (Supplementary Fig. 2b). 
Importantly, the OCR decline was also associated with the specific decrease of mitochondrial 
complex I proteins, as previously reported for SDH-defective neuroendocrine tumours23, and with 
the resulting drop of its catalytic activity (Supplementary Fig. 2c, d). It is worth-noting that, 
approximately 60% of the mitochondrial respiration is coupled to oxidative phosphorylation in 
Sdhbfl/fl cells while SdhbΔ/Δ cells show a reduced coupling efficiency (Supplementary Fig. 2a). This 
indicates that oxidative phosphorylation contributes only marginally to ATP synthesis when SDH 
activity is lost. In line with these respiratory adjustments, the ATP-synthase inhibitor oligomycin 
induced energetic stress in Sdhbfl/fl cells only, preferentially limiting their proliferation (Fig. 1g and 
Supplementary Fig. 2e, f). The respiratory features of SDH-null cells imply that their ATP 
requirements must be fulfilled mainly by glycolysis. In line with this deduction, the reduced OCR 
of SdhbΔ/Δ cells is associated with an increase in the glycolytic flux, as indicated by the augmented 
extracellular acidification rate (Supplementary Fig. 2g) and confirmed by the increase in glucose 
consumption and lactate production rates (Fig. 1h). Importantly, whereas glycolysis inhibition 
elicited by the lactate dehydrogenase (LDH) inhibitor oxamate did not affect the energetic status of 
Sdhbfl/fl cells, it raised the AMP/ATP ratio in SDH-null cells and selectively impaired their 
proliferative potential (Fig. 1g and Supplementary Fig. 2h-j, e, m). 
 
Extracellular pyruvate is required to maintain maximal glycolytic flux and to enable 
proliferation of Sdhb-null cells 
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In order to study the changes in cell metabolism upon SDHB loss, the exchange rate of metabolites 
between cells and the extracellular medium was profiled by LC-MS. In accordance with being the 
major carbon source for the TCA cycle, glutamine was the second most consumed metabolite by all 
cell types, but with different rates (Supplementary Fig. 3a). Interestingly, despite the presence of 
pyruvate in the medium, a net secretion of this organic acid by Sdhbfl/fl cells was observed. On the 
contrary, pyruvate ranks as the third most-consumed metabolite in the SDH-null clones 
(Supplementary Fig. 3a). In agreement with this metabolic feature, pyruvate deprivation selectively 
impaired the proliferation of SdhbΔ/Δ cells, sparing their normal counterparts (Fig. 2a). Whereas 
SdhbΔ/Δ cells consumed pyruvate, this exogenous metabolite contributed only marginally to its 
intracellular pool, as found by incubating cells in U-13C-pyruvate (Supplementary Fig. 3b). 
Moreover, as it is mainly synthesized de novo through glycolysis, the large majority of intracellular 
pyruvate was fully labelled (13C3) in cells cultured with U-13C-glucose (Supplementary Fig. 3c). 
Surprisingly, when pyruvate was deprived from the medium, intracellular steady-state levels of this 
metabolite were dramatically decreased in SdhbΔ/Δ clones, suggesting that the demand for pyruvate 
exceeded the cells’ biosynthetic capacity (Supplementary Fig. 3c). By converting pyruvate to 
lactate, LDH restores the NAD+ pool which is rate-limiting for glycolytic flux. Similarly, an extra 
pool of NAD+ derived from the synthesis of lactate from extracellular pyruvate, may allow SDH-
null cells to maximize their glycolytic capacity and divert some glucose-derived carbons for 
biomass generation (Fig. 2b). In agreement with this hypothesis, the conversion rate of exogenous 
pyruvate into lactate (13C3-Lactate) was almost 2.5 fold higher in SdhbΔ/Δ than in Sdhbfl/fl cells (Fig. 
2c) and the NAD+/NADH ratio was decreased in pyruvate-deprived SdhbΔ/Δ cells, as well as in 
LDH-inhibited cells (Fig. 2d and Supplementary Fig. 2k). As a result of the NAD+/NADH 
unbalance, a marked accumulation of pentose phosphate pathway and glycolytic intermediates 
upstream of the NAD+-dependent oxidation of glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate, was observed in pyruvate-deprived SDH-deficient cells (Fig. 2e). In line with 
these observations, a consequent decrease in glucose-derived lactate (13C3-Lactate) secretion and 
glucose (13C6-glucose) consumption rates were measured upon pyruvate depletion (Fig. 2f), 
demonstrating that SDHB loss constrains cells to the uptake of extracellular pyruvate to sustain 
maximal glycolytic flux.  
 
Glucose-dependent aspartate biosynthesis dictates pyruvate dependency of Sdhb-deficient 
cells 
To obtain further insights on metabolic changes due to SDH loss, an untargeted endo-metabolomic 
profiling coupled with multivariate statistics was performed (Supplementary Table 1). The principal 
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component analysis (PCA) showed a clear separation between SDH-null and SDH-containing cells. 
Moreover, the occurrence of sub-clustering of pyruvate-fed and pyruvate-deprived SdhbΔ/Δ cells, but 
not Sdhbfl/fl cells, indicates that the removal of pyruvate from the medium generates a metabolic 
signature only when SDHB is deleted (Fig. 3a). Metabolite profiling (in the presence of pyruvate) 
revealed that, as expected, succinate is the most increased metabolite in the SDH-deficient cells as 
compared to control cells. Interestingly however, formiminoglutamic acid (FIGLU), a catabolic 
product of histidine, and aspartate, a non-essential amino acid synthesized de novo from 
oxaloacetate, ranked as the first and second decreased metabolites in SDH-null cells (Fig. 3b). 
Furthermore, in agreement with this in vitro observation, these metabolic changes were also 
detected in human SDH-mutated paragangliomas and pheochromocytomas with respect to SDH-
unrelated tumours (Fig. 3c and Supplementary Table 2 and 3), thus validating our in vitro 
observations. Furthermore, the steady state levels of aspartate, but not FIGLU, were further 
dampened by about 4-fold upon pyruvate withdrawal in SdhbΔ/Δ cells, whereas it remained 
unchanged in SDHB-proficient cells (Fig. 3d and Supplementary Table 1). Supporting these 
observations, de novo biosynthesis of aspartate (15N-aspartate) was decreased in SdhbΔ/Δ cells 
cultured with α-15N-glutamine and was further diminished upon pyruvate deprivation (Fig. 3e), 
suggesting that reduced aspartate availability for biomass generation may underlie the pyruvate-
dependency of SDH-deficient cells. In line with this hypothesis, supra-physiological aspartate 
supplementation elevated its intracellular steady-state levels (Fig. 3f) and almost completely 
relieved the pyruvate-addiction of SdhbΔ/Δ cells (Fig. 3g). To further explore the influence of 
exogenous pyruvate availability on aspartate biosynthesis, we analysed the pattern of fractional 13C-
enrichment of this amino acid after culturing cells in the presence of U-13C-pyruvate, U-13C-
glutamine or U-13C-glucose (Fig. 3h). The 13C-enrichment profiles revealed that less than 10% of 
the total aspartate pool contained isotopologues derived from extracellular pyruvate, regardless of 
cell genotype. Rather, approximately 80% of aspartate was derived from glutamine in Sdhbfl/fl cells 
whereas, due to TCA cycle truncation, glutamine carbons contributed to less than 20% of aspartate 
production via reductive carboxylation (13C3) in SdhbΔ/Δ cells. Surprisingly, whereas glucose 
supplied only up to 20% of the aspartate pool in Sdhbfl/fl cells, approximately 45% of aspartate 
carbons were derived from glucose in SDH-null cells. Therefore, as pyruvate accelerates the 
glycolytic flux in SdhbΔ/Δ cells, we postulated that it would also sustain the diversion of glucose-
derived carbons into the aspartate biosynthetic pathway. Accordingly, the relative contribution of 
glucose carbons to the aspartate pool dropped from 45% to 15% in SdhbΔ/Δ cells upon pyruvate 
withdrawal, whereas it remained unaffected in SDH-proficient counterparts (Fig. 3i).  
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Pyruvate carboxylase expression is induced in SDH-deficient cells and SDHx-mutated human 
tumours 
In Sdhbfl/fl cells glucose mainly provides two carbons (13C2-aspartate) to the aspartate skeleton by 
pyruvate oxidation in the TCA cycle via pyruvate dehydrogenase. On the contrary, the U-13C-
glucose-derived aspartate pool of SdhbΔ/Δ cells contained exclusively isotopologues with three 13C 
atoms. This indicated that SDH loss primed cells to engage pyruvate carboxylase to generate 
oxaloacetate (Fig. 3i and 4a). This was further supported by the observation that, in SdhbΔ/Δ cells 
cultured with U-13C-glucose, the fractional 13C-enrichment of malate and fumarate recapitulated 
that of aspartate (Fig. 4a, b and Fig. 1c). Potential increased PC activity (based on the labelling 
pattern of glucose-derived TCA cycle metabolites) was recently observed also in patient-derived 
FH-deficient RCC24, 25. Furthermore it was previously suggested that PC may become essential for 
SDH- and FH-deficient cells26. PCX fixates bicarbonate into pyruvate to generate oxaloacetate. 
Therefore, as an additional test of PCX activity, cells were cultured in the presence of 13C-
bicarbonate and the kinetics of synthesis of 13C1-aspartate and 13C1-malate were monitored. In 
agreement with our related findings, both 13C-labelled metabolites were enriched faster in SDH-null 
cells compared to normal counterparts (Fig. 4c, d). Furthermore, PCX protein level was up-
regulated in SdhbΔ/Δ cells (Fig. 4e) in association with an enhancement in its gene expression (Fig. 
4f), substantiating the increase in enzyme activity. To extend the impact of these findings and to 
gain insights into whether pyruvate carboxylase is related to SDH-deficient cancer pathophysiology, 
we analysed PC expression in SDH-defective human tumours. PC was found induced in SDHx-
mutated paragangliomas and pheochromocytomas with respect to non-SDHx-mutated tumours (Fig. 
4g). In addition, stronger granular cytoplasmic immunostaining of PC was revealed in tumour 
epithelial cells of human SDHB-mutated RCC compared to their normal adjacent renal tissues (Fig. 
4h and Supplementary Fig. 4a).  
 
Pyruvate carboxylase sustains proliferation and tumorigenic capacity of transformed Sdhb-
null cells 
Our findings prompted us to investigate the essentiality of PCX for growth of SDH-deficient cells. 
To this aim, Pcx expression was stably silenced by three independent shRNAs via lentiviral 
infection (Supplementary Fig. 4b). This reduced the incorporation of 13C carbons derived from U-
13C-glucose (Fig. 5a and Supplementary Fig. 4c) or from 13C-bicarbonate (Fig. 5b and 
Supplementary Fig. 4d) into both malate and aspartate, without eliciting appreciable changes in the 
contribution of glutamine carbons to the pool of this amino acid (Supplementary Fig. 4e). 
Furthermore, silencing of Pcx significantly reduced the proliferation of SDH-null cells in vitro, 
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sparing the normal counterparts (Fig. 5c). We then evaluated the role of PCX in vivo by 
xenografting H-RASV12-transformed Sdhbfl/fl and Sdhb∆/∆  cells in immuno-deficient mice after 
silencing PCX expression by two different shRNAs (Fig. 5d and Supplementary Fig. 4f). PCX 
down-regulation in SDH-proficient cells did not result in a significant alteration in tumour initiation 
and growth (Fig. 5e-g and Supplementary Fig. 4g-i). On the contrary, PCX was required to support 
tumorigenesis in SDHB-deficient cells. Indeed, mice xenografted with Sdhb∆/∆-shPcx cells gave rise 
to tumours with a significantly delayed onset in both experiments. It’s worth noting that whereas 
tumour formation was observed only in two out of nine mice xenografted with Sdhb∆/∆-shPcx-1 
cells, tumours emerged in all mice  injected with Sdhb∆/∆-shPcx-5 cells, but exhibited a significantly 
reduced growth with respect to their PCX expressing counterparts (Fig. 5e-g and Supplementary 
Fig. 4g-i). 
 
Pyruvate carboxylase enables growth of Sdhb-null cells by supporting aspartate biosynthesis 
PC is required for the growth of cancer cells under in vitro glutamine-deprived conditions and 
allows cells to use glucose-derived pyruvate, rather than glutamine, for replenishing TCA cycle 
intermediates which are used in cataplerotic reactions, such as fatty acids (palmitate) biosynthesis27. 
However, our results suggest that the engagement of PCX provides SDH-deficient cells with a 
metabolic adaptation that mainly supports aspartate production. Indeed, compared to aspartate, PCX 
contributes marginally to citrate labelling (13C3-citrate and 13C5-citrate) (Supplementary Fig. 5a). 
Moreover, citrate and palmitate steady-state levels remained unchanged in PCX-silenced cells (Fig. 
6a, b), and whereas their proliferative capacity was completely rescued by aspartate 
supplementation, providing excess palmitate to PCX-silenced SDH-deficient cells did not support 
in vitro proliferation (Fig. 6c, d and Supplementary Fig. 5b, c). The rescue of the growth of PCX-
silenced SDH-deficient cells by aspartate also indicates that the effect of both shRNAs used to 
silence PCX is on target.   
 
DISCUSSION 
Cancer cell metabolism is shaped by changing fluxes along key metabolic pathways and altering 
nutrient utilization in order to support biomass accumulation required for continuous mitotic 
divisions. Here, we show that the impairment of mitochondrial bioenergetics due to SDHB 
deficiency results in dependency on extracellular pyruvate to sustain the glycolytic flux and to 
direct glucose-derived carbons into aspartate biosynthesis via pyruvate carboxylase. Whereas the 
anaplerotic oxidative metabolism of glutamine into the TCA cycle allows SDH-proficient cells to 
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replenish TCA cycle intermediates, which are required for the production of cellular building 
blocks, the TCA cycle truncation forces SDH-null cells to rely on PCX to generate oxaloacetate.  
The impact of these findings is strengthened by the histopathological observation that high-
proliferative regions of SDHB-mutated RCC are characterized by higher PC expression in 
comparison to low-proliferative areas in the same tumour and in normal adjacent tubules (Fig. 4h). 
However, although our results suggest a direct link between PC levels and SDHB loss in renal 
cancers and neuroendocrine tumours, induction of PC gene expression may be dispensable, as 
metabolic fluxes through this enzyme can be shaped by allosteric regulation of PC function28 and by 
post-transcriptional modulation of PC protein abundance27. In fact, the extent of the induction of 
Pcx RNA in SDH-deficient cells was inconsistent (compare Fig. 4f to Suppl. Fig. 4b), nevertheless, 
the induction of PCX activity in these cells, as measured by bicarbonate-derived 13C incorporation 
into aspartate, was equivalently high (compare Fig. 4c to Fig. 5b). It is noteworthy that PC was 
recently found to be essential for non-small-cell lung cancer proliferation29. Furthermore, FH 
deficiency24, 25 or the expression of oncogenic IDH1 mutation30, increased anaplerotic contribution 
of pyruvate carboxylation, although no essentiality of PC in these cells was reported.  
Beyond the direct contribution to protein biosynthesis, aspartate is the precursor for 
asparagine as well as pyrimidine and purine nucleotides, and since aspartate is not abundant in 
human plasma, its de novo synthesis is required for cell growth and proliferation. Therefore, by 
relating glycolytic-dependency of SDH-null cells to aspartate biosynthesis via PC, this study 
uncovers a metabolic vulnerability that may be exploited for treatments of malignancies arising as a 
direct consequence of SDH loss-of-function and, possibly, of other TCA cycle defects. 
Furthermore, the evidence that aspartate levels are dramatically depleted in SDHB-deficient cells 
and tumours raises the possibility that a mild inhibition of aspartate amino-transferases could limit 
preferentially their proliferative potential as well. Similarly, because PC fixates bicarbonate into 
pyruvate, inhibition of bicarbonate uptake or synthesis could limit substrate availability for this 
enzyme, thereby offering an additional therapeutic window for the treatment of SDH-mutated 
tumours. 
 
 
AUTHOR CONTRIBUTIONS  
S.C. conceived the study, designed and performed the experiments, interpreted the data, and wrote 
the manuscript; L.Z. performed the untargeted metabolomics analysis; G.M,N.V.D.B S.T, V.B, J.K, 
A.V.V supervised the targeted LC-MS and GS-MS analyses; E.M supervised the generation of 
kidney cells; D.S and D.S generated genetically modified Sdhbfl/fl mice; G.K. performed the 
10 
 
bioinformatics and statistical analyses; C.N. performed immunohystochemistry of human SDHB-
associated RCC; S.F. performed hystopathological analysis of SDHB-related RCC; F.S collected 
and provided human paraganglioma and pheochromocytoma samples; K.B. supervised animal 
work; E.G. conceived and supervised the study, interpreted the data, and revised the manuscript. All 
the authors discussed the results and commented on the manuscript.  
 
ACKNOWLEDGEMENTS 
We would like to acknowledge Saverio Tardito and Zachary T. Schug for comments and 
interpretation of the results, Ayala King for editorial work, Umasuthan Srirangalingam for help in 
human specimen collection and the Beatson Institute mouse facility staff for housing of mice and 
xenografts measurements. 
 
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST 
Eyal Gottlieb is a shareholder and a consultant of MetaboMed Israel, Ltd. 
 
GRANT SUPPORT 
This work was funded by Cancer Research UK. S.C. is recipient of a FEBS long-term fellowship. 
 
REFERENCES 
1. Gaude, E., and Frezza, C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2, 
10 (2014). 
2. Baysal, B.E. et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary 
paraganglioma. Science 287, 848-851 (2000). 
3. Niemann, S. & Müller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 
3. Nature Genet. 26, 268-270 (2000). 
4. Astuti, D. et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause 
susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. 
Genet. 69, 49-54 (2001). 
5. Baysal, B.E. et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic 
patients with head and neck paragangliomas. J. Med. Genet. 39, 178-183 (2002).  
6. Ni, Y. et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden 
and Cowden-like syndromes. Am. J. Hum. Genet. 83, 261-268 (2008). 
7. Burnichon, N. et al. SDHA is a tumour suppressor gene causing paraganglioma. Hum. Mol. 
Genet. 19, 3011-3020 (2010).  
11 
 
8. Frezza, C., Pollard, P.J. & Gottlieb, E. Inborn and acquired metabolic defects in cancer. J. Mol. 
Med. 89, 213-220 (2011).  
9. Gill, A.J. et al. Renal tumours and hereditary pheochromocytoma-paraganglioma syndrome 
type 4. N. Engl. J. Med. 364, 885-886 (2011). 
10. Ricketts, C.J. et al. Succinate dehydrogenase kidney cancer: an aggressive example of the 
Warburg effect in cancer. J. Urol. 188, 2063-2071 (2012).  
11. Williamson, S.R. et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed 
characterization of 11 tumours defining a unique subtype of renal cell carcinoma. Mod. Pathol. 
28, 80-94 (2015). 
12. Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component 
of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153-159 (2004).  
13. Ricketts, C., Woodward, E.R., Killick, P., Morris, M.R., Astuti, D., Latif, F., & Maher, E.R. 
Germline SDHB mutations and familial renal cell carcinoma. J. Natl. Cancer Inst. 100, 1260-
1262 (2008). 
14. Selak, M.A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-
alpha prolyl hydroxylase. Cancer Cell 7, 77-85 (2005). 
15. Xiao, M. et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and 
succinate that are accumulated in mutations of FH and SDH tumour suppressors. Genes Dev. 
26, 1326-1338 (2012). 
16. Letouzé, E. et al. SDH mutations establish a  hypermethylator phenotype in paraganglioma. 
Cancer Cell 10, 739-752 (2013). 
17. Guzy, R. D., Sharma, B., Bell, E., Chandel, N. S., & Schumacker, P. T. Loss of the SdhB, but 
not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-
inducible factor activation and tumourigenesis. Mol. Cell. Biol. 28, 718–731 (2008). 
18. Xiao, M. et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and 
succinate that are accumulated in mutations of FH and SDH tumour suppressors. Genes Dev. 
26, 1326-1338 (2012). 
19. Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate 
hydratase. Nature 17, 225-228 (2011). 
20. Zheng, L. et al. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient 
cancer cells. Cancer Metab. 1, 1-12 (2013) 
21. Zheng, L. et al. Fumarate induces redox-dependent senescence by modifying glutathione 
metabolism. Nat. Communn. 6, 6001 (2015).  
12 
 
22. Housley, S.L. et al. Renal carcinoma with giant mitochondria associated with germ-line 
mutation and somatic loss of the succinate dehydrogenase B gene. Histopathology. 56, 405-408 
(2010). 
23. Favier, J. et al. Warburg effect is genetically determined in inherited pheochromocytomas. 
PLoS One. 4, e7094 (2009). 
24. Mullen, A.R. et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in 
cancer cells with mitochondrial defects. Cell Rep. 7, 1679-1690 (2014). 
25. Yang, C. et al. Metabolic reprogramming for producing energy and reducing power in fumarate 
hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One 8, e72179 
(2013). 
26. Folger, O., Jerby, L., Frezza, C., Gottlieb, E., Ruppin, E. & Shlomi, T. Predicting selective drug 
targets in cancer through metabolic networks. Mol Syst Biol. 7, 501 (2011).  
27. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumour 
cells. Proc. Natl. Acad. Sci. USA. 108, 8674-8679 (2011). 
28. Jitrapakdee, S., & Wallace, J.C. Structure, function and regulation of pyruvate carboxylase. 
Biochem. J. 340, 1-16 (1999). 
29. Sellers, K. et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. 
Clin. Invest. 125, 687-698 (2015). 
30. Izquierdo-Garcia, J.L., Cai, L.M., Chaumeil, M.M., Eriksson, P., Robinson, A.E., Pieper, R.O., 
Phillips, J.J., & Ronen, S.M. Glioma Cells with the IDH1 Mutation Modulate Metabolic 
Fractional Flux through Pyruvate Carboxylase. PLoS One. 22, 9 (2014). 
 
 
  
13 
 
FIGURE LEGENDS 
 
Figure 1. Loss of Sdhb is sufficient to truncate TCA cycle and disable mitochondrial 
respiration. Isotopologues distribution of intracellular succinate and fumarate after incubation for 
24h with either U-13C-glucose (a, c) or U-13C-glutamine (b, d). All data are presented as 
mean±s.e.m of one representative experiment (n=3 wells) independently replicated twice (c, d) and 
three times (a, b). (e) Respiratory profile of the specified cells. Arrows indicate incubation of cells 
with the indicated compounds. Data are presented as mean±s.e.m of n=27 (Sdhbfl/fl), n=31 
(Sdhb∆/∆ – CL 5) and n=29  (Sdhb∆/∆ – CL 7) wells pooled from four independent experiments. (f) 
Fraction of intracellular citrate pool containing two 13C atoms as result of pyruvate dehydrogenase 
activity. Data are presented as mean±s.e.m of one representative experiment (n=3 wells) 
independently replicated twice. (g) Cell number of the indicated cells measured after 96h of 
treatment with 0.5 µM oligomycin or 5 mM oxamate. Data are presented as mean±s.e.m of n=12 
wells pooled from four independent experiments. (h) Rates of the indicated metabolites upon 48h of 
incubation of Sdhbfl/fl and SdhbΔ/Δ cells with U-13C-glucose. The sum of all isotopologues is reported 
for clarity. Data are presented as mean±s.e.m of n=18 wells pooled from three independent 
experiments. In this and all other figures, “wells” represent technical replicate samples set up and assessed 
under identical conditions and in parallel within a single experiment. Raw data of independently repeated 
experiments are provided in Supplementary Table 3. 
 
Figure 2. SDH deficiency commits cells to consume extracellular pyruvate to maintain 
maximal glycolytic flux and cell growth. (a) Number of cells cultured in presence (+) or absence 
(-) of pyruvate measured at the indicated time points. Data are presented as mean±s.e.m of one 
representative experiment (n=4 wells), independently replicated three times. (b) Schematic 
representation of effects of pyruvate consumption on maintenance of NAD+/NADH redox state and 
glycolytic flux. Red and white circles indicate 13C and 12C carbon unit, respectively.  (c) Secretion 
rate of exogenous pyruvate-derived lactate (13C3-lactate) of Sdhbfl/fl and SdhbΔ/Δ cells cultured for 
48h with U-13C-Pyruvate. Data are presented as mean±s.e.m of n=6 wells pooled from two 
independent experiments. (d) Measurement of NAD+/NADH ratio expressed as fold change 
compared to pyruvate-fed Sdhbfl/fl cells (e)  Pentose phosphate pathway and glycolytic intermediates 
in cells cultured for 24h in presence (+) or absence (-) of pyruvate. Data in d, e are presented as 
mean±s.e.m of one representative experiment (n=3 wells), independently replicated twice. (f) 
Exchange rates of the indicated labeled metabolites upon 48h of incubation of Sdhbfl/fl and SdhbΔ/Δ 
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cells with U-13C-glucose in presence (+) or absence (-) of pyruvate. Data are presented as 
mean±s.e.m of n=18 wells pooled from three independent experiments. 
 
Figure 3. Glucose-dependent aspartate biosynthesis dictates pyruvate dependency of Sdhb-
deficient cells. (a) PCA of the untargeted endo-metabolomic screening of Sdhbfl/fl and SdhbΔ/Δ cells 
cultured for 24h in presence (+) or absence (-) of pyruvate. (b) Untargeted metabolic profiling of 
Sdhb-null cells. Each dot represents a metabolite with a fold change >2 or <0.5 and a FDR-
corrected p-value <0.0001. Only metabolites that meet the above-mentioned criteria in two out of 
three independent experiments (n=3 wells per experiment) are presented. * Since in this untargeted 
technique fumarate could not be measured, the fold change of fumarate are derived from results 
presented in Fig.1 c and d. FIGLU, Formiminoglutamic acid. (c) Targeted metabolites profiling of 
n=4 human SDHx-mutated paraganglioma/pheochromocytoma specimens. Data are expressed as 
log10 fold change with respect to n=18 non-SDHx-mutated tumours. ***P < 0.001, ****P < 
0.0001, two-tailed Student’s t-test. (d) Untargeted metabolic profiling of pyruvate-
deprived SdhbΔ/Δ cells. Each point represents a metabolite with a fold change > 2 or < 0.5 and a 
FDR-corrected p-value <0.0001. Only known endo-metabolites that meet the above-mentioned 
criteria in two out of three independent experiments (n=3 wells each) are presented. 
(e) Accumulation of 15N-aspartate in cells incubated with α-15N-glutamine for the indicated time 
in presence/absence of pyruvate. Data are presented as mean±s.e.m (n=3 wells) of one experiment, 
performed once. (f) Aspartate levels in cells cultured for 24h in presence or absence of pyruvate 
and/or 2.5 mM aspartate. Data are presented as mean±s.e.m (n=3 wells) of one representative 
experiment, independently replicated twice. (g) Cell number measured after 96h of culture in 
presence/absence of pyruvate and/or 2.5 mM aspartate. Data are presented as mean±s.e.m of n=16 
wells pooled from four independent experiments. (h) Isotopologues labelling profile 
(mean±s.e.m.) of aspartate in cells cultured for 24h in presence of U-13C-pyruvate, U-13C-glutamine 
(n=6 wells for both conditions, pooled from two independent experiments) or U-13C-glucose (n=9 
wells pooled from three independent experiments). (i) Aspartate levels in cells cultured for 24h with 
U-13C-glucose in presence/absence of pyruvate. Data are presented as mean±s.e.m (n=3 wells) of 
one representative experiment, independently replicated twice.  
 
Figure 4. Pyruvate carboxylase expression is induced in SDH-defective cells and SDHx-
mutated human tumours. (a) Predicted labeling pattern of the indicated metabolites in cells 
cultured with U-13C-glucose. Red and white circles indicate 13C and 12C carbon unit, respectively. 
PDH, Pyruvate Dehydrogenase; PCX, Pyruvate Carboxylase; CS, Citrate Synthase; MDH, Malate 
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Dehydrogenase; GOT, Glutamate-Oxalacetate Transaminase. (b) Abundance of 13C3-Aspartate 
and 13C3-malate in U-13C-glucose-cultured cells. Data in b are presented as mean±s.e.m of n=9 
wells pooled from three independent experiments. Accumulation of 13C1-aspartate (c)  and 13C1-
Malate (d) in cells incubated with 13C-bicarbonate for the indicated time. Data in c, d are presented 
as mean±s.e.m of n=3 wells of one representative experiment, independently replicated twice. (e) 
Western blot analysis of PCX protein levels in the indicated cells. Image representative of two 
independent experiments. (f) qPCR analysis of PCX mRNA levels in the indicated cells. Data are 
presented as mean±s.e.m of n=9 wells pooled from three independent experiments. (g) qPCR 
analysis of PC mRNA levels in the n=4 human SDHx-mutated paraganglioma/pheochromocytoma 
specimens. Data are expressed as fold change with respect to n=18 non-SDHx mutated tumours. 
**P < 0.01. two-tailed Student’s t-test.  (h) Immuhistochemical assessment of PC levels in a human 
SDHB-mutated RCC (Tumour ID 21542, details are reported in Supplementary Table 2). The cell 
proliferation marker Ki-67 identifies iperproliferative neoplastic areas of the section. N.A.T., 
normal adjacent tissue; T., tumour. Scale bars = 100 µM.  
 
Figure 5. Pyruvate carboxylation is a vulnerable adaptation to Sdhb loss. (a) Aspartate 
abundance in PCX-silenced cells cultured for 24h with U-13C-glucose. Data are presented 
as mean±s.e.m of n=9 wells pooled from three independent experiments. (b) Relative abundance 
of 13C1-aspartate in PCX-silenced cells incubated with 13C-bicarbonate for 10 min. Data are 
presented as mean±s.e.m of n=3 wells of one representative experiment, independently replicated 
twice. (c) Data are presented as mean±s.e.m of n=12 wells pooled from three independent 
experiments.. (d) PCX expression in H-RasV12-transformed cells infected with lentiviruses 
expressing either a shNTC or shPcx-1 sequence prior to injection into nude mice. Data are 
presented as mean±s.e.m (n=3 wells) of one experiment, performed once. (e-g) In vivo growth of 
cells described in (d) xenografted in athymic nude mice. The % of tumour-free mice over time (e) 
and the tumour volumes of each xenografted mouse (f, g) are presented (n=8 Sdhbfl/fl-shNTC, n=8 
Sdhbfl/fl-shPcx1, n=9 Sdhb∆/∆-shNTC, n=9 Sdhb∆/∆-shPcx1). The Log-rank (Mantel-Cox) test was 
used to calculate the statistical significance between curves in (e). A statistical permutation test was 
used to compare the statistical significance between curves of the selected genotypes in (f), as 
described in Methods. Data derive from one experiment, performed once.  
 
Figure 6. Pyruvate carboxylase supports growth of Sdhb-null cells by sustaining aspartate 
biosynthesis. (a) Citrate abundance in PCX-silenced cells cultured for 24h with U-13C-glucose. 
Data are presented as mean±s.e.m of n=9 wells pooled from three independent experiments. (b) 
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Effect of PCX silencing on the total intracellular palmitate levels. Data are presented as mean±s.e.m 
(n=3 wells) of one experiment, performed once. (c) Number of PCX-silenced cells in the presence 
(+) or absence (-) of 2.5 mM aspartate measured after 96h of culture. Data are presented as 
mean±s.e.m (n=4 wells) of one experiment, performed once. (d) Number of control and PCX-
silenced cells supplemented with 50 µM palmitate measured after 96h of culture. Data are presented 
as mean±s.e.m (n=4 wells) of one experiment, performed once.  
1 
 
METHODS 
 
Generation of conditional Sdhb mice and immortalized Sdhb-null mouse kidney cells. A DNA 
fragment comprising 240bp homology arms flanking an F3-KAN-F3-LoxP cassette was 
recombineered into intron 3-4 of the Sdhb gene of a pool of three BAC clones in the EL250 strain 
of E.coli31. Subsequent expression of Flp in these cells allowed excision of the Kanamycin-
resistance gene. The same cells were then subjected to recombineering with a DNA fragment 
comprising 120bp and 400bp homology arms flanking an FRT-HYG-FRT-LoxP cassette into intron 
2-3.The plasmid pFlexDTA, a modified version of pFlexible32, was linearised by NotI-AscI and a 
retrieval fragment cloned into these sites. This comprised 1140bp of homology sequence bisected 
by a SwaI site to allow for subsequent linearization. The homology arms of this plasmid are 
approximately 5kb distal to the Hygro cassette on the BAC DNA. The resultant SwaI-linearised 
vector was used to retrieve DNA sequence from the modified Sdhb locus by recombineering to 
generate the targeting vector transfected in mid-log phase G4 mESCs (129S6/SvEvTac x 
C57BL/6Ncr F1)33 by electroporation. Electroporation was performed under standard conditions 
(250V; 500µF; infinite resistance; cuvette width: 4mm) in a Biorad GenePulser XCell with 
capacitance extender. After plating onto DR4 irradiated MEF monolayers34, cells were placed under 
Hyg selection for 6-7 days. Individual colonies were picked on to 96-well plates for 
cryopreservation and further analysis. Correct targeting of the vector to the Sdhb locus on both the 
5’ and 3’ sides was confirmed using PCR on genomic DNA prepared from Hyg-resistant colonies. 
PCR genotyping was done using Expand Long Template (Roche) according to the manufacturer's 
recommendations. The presence of the isolated LoxP/F3 sequence in intron 3-4 was confirmed 
separately. Following confirmation of targeting by PCR, clones were recovered and expanded under 
Hyg-ESC medium prior to re-confirmation by PCR. Following identification of correctly targeted 
clones, mouse lines were derived by injection of Sdhbwt/fl ES cells into C57BL/6J blastocysts 
according to standard protocols35. Following breeding of high percentage male chimeras, germline 
offspring were identified by coat colour and the presence of the modified allele was confirmed by 
PCR across the isolated LoxP/F3 sequence as described above. Sdhbwt/fl mice were then intercrossed 
to obtain Sdhbfl/fl mice that were used to isolate primary epithelial kidney cells following the method 
described previously36. Sdhbfl/fl cells were immortalized by infection with the pBABE-
Hygro Retroviral Vector carrying the SV40 T-Ag gene, kindly provided by Dr. Peter D. Adams 
(Cancer Research UK, The Beatson Institute for Cancer Research). 1x 105 Sdhbfl/fl cells were 
then either left untreated or infected with 200 p.f.u/cell of  a Cre recombinase-encoding adenovirus 
(Ad5-CMV-Cre-GFP, Vector Development Laboratory). After 3 days of infection, a clonal 
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approach by limiting dilution was used to obtain homogenous Sdhb-deleted (SdhbΔ/Δ) cells. The 
cells were negative for Mycoplasma infection and were maintained at 37°C in a 5% CO2 
atmosphere in air using 25 mM glucose and 1 mM pyruvate-containing DMEM (21969-035, Gibco, 
Lyfe Technologies) supplemented with 10% FBS and 2 mM glutamine. All cell lines used in this 
paper are not listed in the database of commonly misidentified cell lines maintained by ICLAC and 
NCBI Biosample. 
DNA and RNA extraction.  Genomic DNA (gDNA) and RNA were extracted using, respectively, 
the QIAamp® DNA Blood Mini Kit (51104, Qiagen) and RNeasy Mini Kit (74104, Qiagen) 
following manufacturer’s instructions. All nucleic acids were quantified by the Eppendorf 
Biophotometer using Eppendorf single sealed cuvettes, UVette (952010051, Eppendorf UK 
Limited). gDNA was assessed to determine the genotypes of the different cell lines using the 
primers: 3LoxP U1 (5’-CATTGTGGTCCTTGGCACAG-3’), 3LoxP D1 (5’-
AAGGGCGTTGTCTTCTCACC-3’) and Hyg U1 (5’-CTTGTATGGAGCAGCAGACG-3’). The 
PCR of gDNA was performed using GoTaq DNA polymerase (Promega) and 0.5 µM primers 
following the manufacturer’s indications. The PCR program was: 120 s at 95 °C followed by 33 
cycles of 30 s at 95 °C, 60 s at 63 °C and 60 s at 72 °C.  
qPCR analyses. For Real-Time (qPCR) analysis, 2 µg of total RNA was retro-transcribed into 
cDNA using SuperScript® VILOTM reverse transcriptase (11755-050, Invitrogen, Life 
Technologies). cDNAs were mixed with the Fast SYBR® Green Master Mix (4385612, Applied 
Biosystems) according to the manufacturer instruction and 4 pmol of both forward and reverse 
primers for: 
Pcx (forw. 5’-GGCGCATGAGTTCTCCAACA-3’; rev. 5’-GTAGGCCCGGGTGTAATTCTC-3’) 
or PC (forw. 5’CCAGAGGCAGGTCTTCTTTG-3’; rev. 5’- GGCCCTTCACGTCCTTTAG-3’). 
qPCR was performed by the 7500 Fast Real-Time PCR System (Applied Biosystems) and the 
amplification steps were 95°C for 20 s, followed by 40 cycles of 95°C for 3 s and 60°C for 30 s. 
The relative quantitation of each mRNA was performed by the comparative ∆∆Ct method using β-
actin for normalization. 
Cell number assessment. Cells were plated at 1x104 cells/well in 24-well plates. At the specified 
experimental time, each well was washed once with PBS, trypsinized, re-suspended in a Casyton 
solution and counted with a Casy cell counter. 
Measurement of OCR and ECAR rate. 2x104 Sdhbfl/fl cells and 3x104 SdhbΔ/Δ cells were plated 
onto XF96 plates (09814, Seahorse Bioscience) and incubated at 37 °C, 5% CO2 for 24 h. The 
medium was then replaced with 150 µl of unbuffered assay media (Seahorse Bioscience) 
supplemented with 25 mM glucose, 2% FBS, 1mM pyruvate (pH 7.4) and cells were then placed at 
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37 °C in a CO2-free incubator for 45 minutes. Oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) were then recorded using the XF96 Extracellular Flux Analyzer 
(Seahorse Bioscience). OCR and ECAR were normalized  to the protein content in each well 
calculated at the end of the experiments by the Lowry assay.  One µM oligomycin A, 0.75 µM 
CCCP and 1 µM antimycin A were added to measure ATP-coupled, maximal, and mitochondrial-
dependent basal OCR, respectively as previously reported37.  
Measurement of SDH activity. The activity of SDH (succinate:coenzyme Q oxidoreductase 
activity) was measured by a spectrophotometric assay as described previously38.  
Measurement of the mitochondrial mass. Mitochondrial mass was assessed cytofluorimetrically 
by measuring the incorporation of 100 nM the mitochondrial potential-insensitive 
dye MitoTracker Green FM (Life Technologies) as described previously39. 
Mitochondria isolation and measurement of Complex I activity. Mitochondria were isolated 
from Sdhbfl/fl and Sdhb∆/∆ cells as previously described40 and used to determine levels of several 
mitochondrial proteins by immunoblotting and to assess the activity of Complex I by the dipstick 
assay kit (Abcam, ab109720), according to manufacturer instructions. 
Immunoblotting. Cells were washed twice with cold PBS and lysed in RIPA buffer  supplemented 
with protein and phosphatase inhibitor cocktails. Protein concentration was determined by the 
Bicinchoninic Acid Assay (Thermo scientific) using BSA as a standard. Equal amounts of protein 
were mixed with Laemmli buffer 2x warmed at 95°C for 5 min, and loaded on 4-12% gels for SDS-
PAGE. After electrophoretic separation, proteins were blotted onto 0.22 mm nitrocellulose 
(Millipore), blocked with 10% non-fat milk in TBS-Tween, and incubated at 4°C overnight with the 
following antibodies: anti-succinate dehydrogenase b (goat polyclonal Santa Cruz Biotech sc-
34150, 1:500), anti-β-tubulin (mouse monoclonal Sigma-Aldrich, T5201, 1:10000), anti-pyruvate 
carboxylase (rabbit monoclonal Abcam, ab126707, 1:1000), anti-NDUFS4 (mouse monoclonal, 
Abcam, Ab87399, 1:1000), anti-MTND6 (mouse monoclonal, Invitrogen, A31857, 1:1000), anti-
COX IV (rabbit polyclonal, Abcam, Ab16056, 1:2000), anti-membrane integrity WB cocktail 
(mouse monoclonal, Abcam, Ab110414, 1:1000). Membranes were then washed and incubated with 
secondary anti-mouse (926-32212 or 926-32222, LI-COR), anti-rabbit (926-68073, LI-COR) or 
anti-goat (926-32214, LI-COR) at 1:10000 dilution. The IR scanning was performed using Licor 
Odyssey scanner (channel, 700 and 800) and acquired using Image Studio 2.0. 
Metabolites Extraction and LC-MS. Sdhbfl/fl and SdhbΔ/Δ cells were plated in 6-well plates in 25 
mM glucose and 1 mM pyruvate-containing DMEM (21969-035, Gibco, Lyfe Technologies) 
supplemented with 10% FBS and 2 mM glutamine at 2x105 and 3x105 cells/well, respectively. After 
24h the medium was replaced with DMEM (11966-025, Gibco, Lyfe Technologies) supplemented 
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with 10% FBS, 25 mM uniformly labeled (U-13C) or unlabelled glucose in presence of 1 mM U-13C 
or unlabelled pyruvate. For pyruvate-deprivation experiments, the above medium devoid of 
pyruvate was used. For U-13C-glutamine-tracing experiments, complete DMEM (21969-035, Gibco, 
Lyfe Technologies) supplemented with 10% FBS and 4 mM U-13C-glutamine was used. For α-15N-
glutamine-tracing assays, cells were plated in 25 mM glucose and 4 mM glutamine-containing 
custom made DMEM supplemented with 10% FBS with or without 1 mM pyruvate. After 24h, 
media were replaced with the same medium containing both 2 mM unlabelled and 2 mM α-15N-
glutamine in presence or absence of 1 mM pyruvate. For 13C-bicarbonate-tracing experiments, 24h 
after cell plating, media were replaced with DMEM (12800-017, Gibco, Lyfe Technologies) 
supplemented with 10% FBS and 20 mM sodium bicarbonate. After 8 hours, cells were incubated 
with 13C-labelled or unlabelled 24 mM bicarbonate.   
Cells were cultured in the above specified conditions for 24h (if not otherwise indicated), for 
intracellular metabolites (endo-metabolites) determination, or for 48h, to analyze metabolites 
present in the medium (exo-metabolites). At the end of the incubations, monolayers were rapidly 
washed 3 times with ice-cold PBS and extracted with 600 µl of ice-cold extraction solution, 
composed of methanol, acetonitrile, and water (5:3:2), for endo-metabolites determination. 
Alternatively, an aliquot of the media was diluted in extraction solution for exo-metabolites 
analyses. Media derived from wells lacking of cells but incubated in the same conditions were used 
as a reference to quantify the exchange rate (consumption/secretion) of exo-metabolites. Both 
media and cell extracts were centrifuged at 16,000g for 30 min at 4°C and the supernatants were 
analyzed by LC-MS.  For exo-metabolites quantification, aliquots of DMEM media were processed 
similarly and supplemented with known concentrations of either U-13C labelled metabolites or 
essential and non-essential amino acids to prepare calibration curves. Endo-metabolites were 
normalized to the protein content in each well calculated, at the end of the experiment, by the 
Lowry assay. The exchange rates were obtained normalizing the variation in consumption or 
secretion of each exo-metabolite to the average protein content of each samples since the beginning 
of the experiment (t = 0h) to its end (t = 48h). For the measurement of fumarate and its 
isotopologues, a Q-Exactive Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany) 
was used together with a Thermo Scientific Dionex Ultimate 3000 HPLC system. The HPLC setup 
consisted of a ZIC-HILIC column (150mm x 4.6mm, 5µm, SeQuant, Merck KGaA, Darmstadt, 
Germany), preceded with a guard column SeQuant ZIC-HILIC (20mm x 2.1mm). The aqueous 
mobile phase solvent is 0.1% formic acid in water and the organic mobile phase is 0.1% formic acid 
in acetonitrile. The mobile phase gradient runs from 80% organic mobile phase to 50% over the 
first 12 minutes, is then maintained at 50% organic mobile phase for the next 14 minutes, increased 
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and maintained at 20% organic mobile phase for 8 minutes, and then equilibrated back to 80% 
organic mobile phase. The flow rate used is 300µl/min and the column temperature is maintained at 
30°C. Samples are maintained at 4°C in a chilled autosampler, prior to injection. The total analysis 
time is 45min and 5µl of sample is injected. The Q-Exactive mass spectrometer was operated in full 
scan mode, with electrospray (ESI) ionization and polarity switching, over a mass range of 75-1000 
m/z at a resolution of 35,000 (at 200m/z). The Q-Exactive was also used in SIM (Selected Ion 
Monitoring) mode, for improving sensitivity, where only fumarate and its isotopologues were 
monitored by the mass spectrometer, using negative ion mode and a resolution of 70,000 (at 
200m/z). The mass accuracy for both methods was below 5ppm. Data were acquired with Thermo 
Xcalibur software. The peak areas of fumarate and its isotopologues were determined using Thermo 
LCquan software, identified by the exact mass of each singly charged ion and by known retention 
time on the HPLC column. For the unbiased metabolomics analysis and the targeted analysis of all 
the other metabolites, cell and medium extracts were injected on a ZIC-pHILIC column (SeQuant, 
150 x 2.1mm, 5µm). Mobile phase C: 20 mM ammonium carbonate, pH 9.4. Mobile phase D: 
acetonitrile. The flow rate was 100 μL/min over the gradient as follows: 0 minutes 80% D to 30 
minutes 20% D and the column was then re-equilibrated until 38 minutes at 80%D.  All metabolites 
were detected over a mass range of 75-1000 m/z using the Exactive Orbitrap mass spectrometer 
(Thermo Scientific, Waltham, MA, USA) with electrospray (ESI) ionization and polarity switching. 
Determination of lipogenic AcCoA. Isotopic enrichment in palmitate in cells incubated for 72h 
with U-13C-glucose or U-13C-glutamine were quantified by LC-MS and the fraction of labelling of 
lipogenic AcCoA was inferred from that of palmitate, using the bionomial model introduced by 
Kamphorst et al41.  The synthesis of palmitate results in the incorporation of 8 acetyl groups from 
AcCoA into palmitate. Each acetyl unit can be unlabelled (M+0) or fully labelled (M+2). If p is the 
M+2 fraction then the expected M+2x (x=1,…,8) fractions (P) of palmitate follow the bionomial 
model (eq. 1). 
(eq. 1)    
We determined p by fitting the value resulting in the minimum mean squared deviation between the 
predicted (eq. 1) and the observed values (fraction at each isotopologues). 
Palmitate quantification and GS-MS. For quantification of total intracellular palmitate level, the 
cells were cultured in 6-well plates. At time of extraction, medium was aspirated, cells rinsed twice 
with 1 mL room temperature PBS, 0.75 mL of methanol/PBS (1:1, v/v) solution at -20°C added, 
and the plates kept at -20°C for 10 min. Cells were then scraped into a glass tube (Fisher Scientific), 
chloroform (0.5 ml) and  internal standard mixture (20 µL of 50 µg/mL TAG 14:0/17:1/18:1 and 
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PC 17:0/17:0 (Avanti Polar Lipids)) added, the mixture vortexed for 1 min and then centrifuged at 
500 g for 10 min, and the chloroform layer transferred to a new glass vial. The extract was dried 
under N2, followed by trans-esterification and formation of fatty acid methyl esters (FAMEs) by 
heating the lipid extract at 100°C with 80 µL of toluene, 600 µL of methanol and 120 µL of 
methanolic-HCl for 60 min. Thereafter, 400 µL of water was added to the reaction mixture and 
FAMEs were extracted with 300 µL of hexane and analysed by GC-MS. FAMEs were separated on 
an Agilent 7890B GC system with a Phenomenex ZB-1701 column (30m x 0.25mm x 0.25 µm), 
coupled to an Agilent 7000 Triple Quadrupole GC/MS system. GC-MS parameters and temperature 
program were as previously described42. Peak integration was performed with Agilent Mass Hunter 
B.06.00 software. Peak height of methyl palmitate (C16:0) was normalized to both methyl 
heptadecanoate (C17:0) and heptadecenoate (C17:1), and calculated value was used to determining 
the amount of palmitate (in ng) in sample by employing calibration curve. 
Short hairpin (shRNA) interference of mouse Pcx. The lentiviral non-targeted shNTC and 
shRNA plasmids against Pcx were purchased from Sigma-Aldrich and identified as follows:  
shPcx-1, TRCN0000112425 
(CCGGCCCTTCAGCTATTTGTCCTTTCTCGAGAAAGGACAAATAGCTGAAGGGTTTTTG) 
shPcx-4, TRCN0000112428 
(CCGGGCACTACTTCATCGAGGTCAACTCGAGTTGACCTCGATGAAGTAGTGCTTTTTG) 
shPcx-5, TRCN0000112429 
(CCGGCTTTCGCTCTAAGGTGCTAAACTCGAGTTTAGCACCTTAGAGCGAAAGTTTTTG).  
Lentiviral infections were carried out as previously described19. Infected cells were incubated with 
medium containing 4 µg/ml puromycin (selection medium) for additional 48h before being used for 
further experiments. 
Immunohystochemistry (IHC) of human SDHB-associated RCC. Six microns cut paraffin 
embeded tissue slices of SDHB-associated RCC and non-neoplastic adjacent kidney tissue were 
immunostained by the Dako Autostainer for PC (Sigma-Aldrich, HPA043922) and Ki-67 (Dako, 
M7240). Epitope retrieval was performed at 98°C in Tris-EDTA retrieval buffer, pH8. Samples 
were counterstained with haematoxylin, dehydrated and coverslipped. The diagnostic mutational 
analysis was performed by the East of Scotland Regional Genetics service by using NHS 
standardised mutation screening procedures. PCR amplification was carried out on Hamilton 
Starlet. Bidirectional sequencing of all exons was performed by the ABI Prism 3730 and Mutation 
Surveyor. 
Analyses of human paragangliomas and pheochromocytomas. Pheochromocytoma/ 
Paraganglioma susceptibility genes (SDHA, B, C, D, AF2, RET, VHL, MAX and TMEM127) have 
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been analysed for point mutations and small deletions/insertions in 22 samples available for this 
study. Bidirectional sequencing of the coding regions and splice sites was performed on a 
ABI3130xl Genetic Analyzer and analysed by SeqScape Software. MLPA analysis (VHL p016c2; 
SDHB,C,D,AF2 p226b2; MAX,SDHA p429b1) and semiquantitative multiplex-PCR (TMEM127) 
have been performed to evaluate for a deletion/duplication of one or more exons of these genes and 
analysed with Coffalyser.net software. RNA was isolated by TRIzol ® Reagent (Ambion) following 
manufacturer’s indications and further processed as described above. Tumour metabolites were 
extracted by incubating 40 mg of tumour tissue in 1 ml of ice-cold extraction solution and further 
processed as described above. 
Tumour xenografts. Sdhbfl/fl and Sdhb∆/∆ - CL 7 cells were transformed by pWZL retroviral vector 
encoding H-RasV12 oncogene34 kindly provided by Prof. Karen Vousden (Cancer Research UK, 
Beatson Institute), infected with a non-targeted shRNA (shNTC) or shRNA against Pcx and 
selected with 4 µg/ml puromycin for 7 days. In a first experiment, 2 × 106 transformed shNTC and 
shPcx-5 cells were subcutaneously injected in the rear flanks of 10 female 6-week old Balb\c Nu 
nude mice. In a second experiment, 1 × 106 transformed shNTC and shPcx-1 cells were 
subcutaneously injected in the rear flanks of 8 (for Sdhbfl/fl cells) and 9 (for Sdhb∆/∆ cells) male 6-
week old Balb\c Nu nude mice. No statistical method was used to predetermine sample size. 
Tumour lengths (L) and widths (W) of sagittal sections were measured 3 times per week by manual 
caliper and tumour volumes were calculated by the formula tumour volume = 0.5xLxW2. Tumour 
onset was defined by the presence of a tumour mass with a volume ≥ 40 mm3 recorded in at least 
two consecutive measurements. The fractions of tumour-free mice were determined by GraphPad 
Prism and their statistical analyses were performed by using the Log-rank (Mantel-Cox) Test. 
Where applicable, a statistical permutation test (http://bioinf.wehi.edu.au/software/compareCurves/) 
was used to compare the statistical significance between curves of the selected genotypes. Ten 
thousands permutations were used in each analysis. The experiments were not randomized and the 
investigators were not blinded to allocation during experiments and outcome assessment. 
Ethical approval of human and animal studies. The study of human samples included in this 
manuscript was approved by the Tayside Tissue Bank research ethics committee (TR000106 and 
TR000341), Ethics Committee of the COR (Regional Cancer Center) and of the Veneto Institute of 
Oncology Padova (Italy). Informed consent was obtained from all subjects. Animal work was 
carried out with ethical approval from University of Glasgow under the Animal (Scientific 
Procedures) Act 1986 and the EU Directive 2010 (PPL 60/4181). Animals were housed in 
individual ventilated cages in a barrier facility proactive in environmental enrichment. 
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Reagents. U-13C-glutamine (CLM-1822), U-13C-Glucose (CLM-1396-5), U-13C-Pyruvate (CLM-
2440) and α-15N-glutamine (NLM-1016) were from Cambridge Isotopes Laboratories; 13C-
bicarbonate (372382), L-aspartate (A8949) and Sodium Oxamate (O2751) and all remaining 
reagents were obtained from Sigma-Aldrich. 
Statistical Analyses. Two-tailed Student’s t were performed with Graph Pad Prism 5.01 software 
(GraphPad Software Inc). When unequal variances between experimental groups were computated, 
Welch’s correction was applied. Raw data of independently repeated experiments are provided in 
Supplementary Table 3. Statistical analyses were performed using the number of wells as the sample size 
(n). Wells represent technical replicate samples set up and assessed in parallel within a single experiment 
using identical conditions. Details on the numbers of wells assessed and the number of times experiments 
were performed independently are provided in every figure legend. Bioinformatic processing and 
statistical analysis of the untargeted metabolomic data. Log transformed metabolic intensities 
were analysed in R using Limma package implementing moderated t-statistic with Empirical Bayes 
correction and Benjamini and Hochberg adjusted p-values. Three dominant principal components 
analysis43, built on metabolites displaying a maximal coefficient of variance <0.1, depicts the effect 
of genotype and treatment in the data. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1. Generation of Sdhb-deficient cells. (a) Schematic representation of the 
mouse Sdhb genomic locus and Sdhb targeted allele. Numbers specify exons, arrowheads indicate 
LoxP sites; Hyg, Hygromycin-resistance gene cassette. 3 LoxP U1, 3 LoxP D1 and Hyg U1 primers 
were used for genotyping. (b) Bright-field images of Sdhbfl/fl and SdhbΔ/Δ cells. Scale bar = 280 µm. 
(c) PCR analysis of gDNA of kidney epithelial cells of the indicated genotypes after infection (Cre) 
with Ad5-CMV-Cre-GFP; bp, base pairs. (d) Western blot analysis of SDHB levels of the indicated 
cells. Data in b-d derive from one experiment, performed once. (e) Determination of SDH activity 
of the indicated cells in the presence (+) or absence (-) of 20 mM malonate. Data are presented as 
mean±s.e.m of n=3 wells pooled from three independent experiments. (f) % labelling of lipogenic 
AcCoA from glucose and glutamine. Data are presented as mean±s.e.m (n=3 wells) of one 
experiment, performed once. 
 
Supplementary Figure 2. Sdhb loss induces Warburg-like bioenergetic features. (a) Maximal 
and ATP-coupled respiration. Dashed line indicates the relative basal mitochondrial OCR. Data are 
presented as mean±s.e.m of three reading cycles of n=27 wells pooled from four independent 
experiments. (b) Mitochondrial mass; a.u., arbitrary units. Data are presented as mean±s.e.m of n=3 
wells pooled from three independent experiments. (c) Representative Western blot analysis (out of 2 
independent experiments) of the levels of two complex I subunits (red) and several mitochondrial 
proteins (green) assessed in the indicated mitochondrial extracts. (CI, Complex I; CVa, ComplexVa, 
CIII Core1, Complex III Core 1, CypD, Cyclophilin D, Cyt c, Cytochrome c, COX IV, Cytochrome 
c Oxidase). (d) Mitochondrial Complex I activity. Data are presented as mean±s.e.m (n=4 wells) of 
one experiment, performed once. (e, f) AMP/ATP ratio (expressed as fold change compared to 
untreated Sdhfl/fl cells), AMP and ATP levels (expressed as % of untreated Sdhfl/fl cells) upon 
treatment of the indicated cells with 0.5 µM oligomycin for 8h. (g) ECAR of the indicated 
cells. Data are presented as mean±s.e.m of n=21 (Sdhbfl/fl) and n=23 (Sdhb∆/∆ ) wells pooled from 
three independent experiments. (h) Lactate secretion by Sdhbfl/fl and SdhbΔ/Δ cells cultured for 48h 
with U-13C-glucose in presence/absence of 5 mM oxamate. The sum of all isotopologues is reported 
for clarity. Data are presented as mean±s.e.m (n=6 wells) of one experiment, performed once. (i, j) 
AMP/ATP ratio (expressed as fold change compared to untreated Sdhfl/fl cells), AMP and ATP 
levels (expressed as % of untreated Sdhfl/fl cells) upon treatment with 5 mM oxamate for 24h. (k) 
NAD+ and NADH levels (expressed as % of Pyruvate-fed Sdhfl/fl cells) in cells incubated for 24 h in 
the presence/absence of pyruvate. Data in e, f, k are presented as mean±s.e.m (n=3 wells) of one 
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representative experiment, independently replicated twice. (l, m) NAD+/NADH ratio (expressed as 
fold change compared to untreated Sdhfl/fl cells), NAD+ and NADH levels (expressed as % of 
untreated Sdhfl/fl cells) in cells incubated for 24h in the presence/absence of 5 mM oxamate. Data in 
i, j, l, m are presented as mean±s.e.m (n=3 wells) of one experiment, performed once. 
 
Supplementary Figure 3. Pyruvate-dependency of Sdhb-deficient cells. (a) Determination of 
secretion (positive bars) and consumption (negative bars) rates of the indicated metabolites of cells 
cultured for 48h with U-13C-glucose. The sum of all isotopologues is reported for clarity. Data are 
presented as mean±s.e.m of n=18 wells pooled from three independent experiments. (b) 
Isotopologues labeling profile of intracellular pyruvate in cells incubated for 24h with U-13C-
pyruvate. (c) Labeling of pyruvate after incubation of cells for 24h with with U-13C-Glucose in 
presence (+) or absence (-) of pyruvate. Data in b, c are presented as mean±s.e.m (n=3 wells) of one 
representative experiment, independently replicated twice.  
 
Supplementary Figure 4. Essentiality of pyruvate carboxylase for growth of Sdhb-deficient 
cells. (a) Immuhistochemical assessment of PC levels in two human SDHB-related RCC samples. 
N.A.T., normal adjacent tissue; T., tumour. Scale bars = 100 µM. Numbers on the left indicates the 
Tumour ID described in Supplementary Table 2. (b) qPCR analysis of Pcx expression in cells 
infected with lentiviruses expressing either a non-targeting shRNAsequence (shNTC) or an shRNA 
targeting Pcx. (c) Measurement of malate levels in cells treated as in (b) cultured for 
24h in presence of U-13C-glucose. Data in b, c are presented as mean±s.e.m of n=9 wells pooled 
from three independent experiments. (d) Abundance of 13C1-malate in cells treated as in (b) 
incubated for 10 min in presence of 13C-bicarbonate. Data are presented as mean±s.e.m (n=3 
wells) of one representative experiment, independently replicated twice. (e) Measurement of 
Aspartate levels in cells treated as in (b) cultured for 24h in presence of U-13C-glutamine. (f) PCX 
expression in H-RasV12-transformed cells infected with lentiviruses expressing either a shNTC or 
shPcx-5 sequence prior to injection into nude mice. Data in e, f are presented as mean±s.e.m (n=3 
wells) of one representative experiment, performed once. (g-i) In vivo growth of cells described in 
(f) xenografted in athymic nude mice. The % of tumour-free mice over time (g) and the tumour 
volumes of each xenografted mouse (n=10 mice per group) (h, i) are presented. The Log-rank 
(Mantel-Cox) test was used to calculate the statistical significance between curves in (g). A 
statistical permutation test was used to compare the statistical significance between curves of the 
selected genotypes in (h) and (i), as described in Methods. Data derive from one experiment, 
performed once.  
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Supplementary Figure 5. Pyruvate carboxylation sustains aspartate biosynthesis. (a) 
Measurement of citrate levels in cells cultured for 24h in presence of U-13C-glucose. (b) Number of 
control and PCX-silenced cells supplemented with 2.5 mM aspartate measured after 96h of culture. 
Data are presented as mean±s.e.m (n=4 wells) of one representative experiment, performed once. 
Data related to shNTC control cells are shared with Fig. 6C (c) Determination of total intracellular 
palmitate levels in PCX-silenced cells supplemented with 50 µM palmitate for 24 h. Data in a, c are 
presented as mean±s.e.m (n=3 wells) of one representative experiment, performed once.  
 
Supplementary Table 1. Unsupervised endo-metabolomic analysis of SDHB-null cells 
 
Supplementary Table 2. Genetic details of human tumour samples analyzed in this study 
 
Supplementary Table 3. Extended data source related to Fig. 3c 











